Home > Insider Trading > Filing (0000899243-21-011749)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1815442	Kymera Therapeutics Inc.	KYMR	Biological Products, (No Disgnostic Substances) (2836)	812992166

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1821198	Jared Gollob	C/O Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown MA 02472	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-11	2,200	$1.31	49,747	No	4	M	Direct
Common Stock	Disposition	2021-03-11	4,695	$60.05	45,052	No	4	S	Direct
Common Stock	Acquisiton	2021-03-15	7,800	$1.31	52,852	No	4	M	Direct
Common Stock	Disposition	2021-03-15	10,305	$60.17	42,547	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-11	2,200	$0.00	2,200	$1.31
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-15	7,800	$0.00	7,800	$1.31

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
67,807		2028-10-31	No	4	M	Direct
60,007		2028-10-31	No	4	M	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.385. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.